LDLR and cardiovascular disorder: Widely considered as the greatest advancement in our understanding of cardiovascular disease (CVD) since the discovery of the low-density lipoprotein (LDL) receptor (LDLR) over 40 years ago, the characterization of the proprotein convertase subtilisin/kexin type-9 (PCSK9) gene and its encoded protein product was published in two back-to-back articles by Seidah et al. and Abifadel et al. in 2003 [1,2].